Fresenius Kabi’s biosimilar Tyenne®* becomes first tocilizumab biosimilar approved by the European Commission

The European Commission (EC) has approved Fresenius Kabi’s tocilizumab biosimilar Tyenne^®*. It is the first tocilizumab biosimilar approved by the EC and Fresenius Kabi’s third approved biosimilar in Europe. This approval is another crucial milestone in the company’s Vision 2026 growth strategy.

* Tyenne^® (tocilizumab) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.